Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Mexiletine

  • Review Articles
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%. Peak plasma concentrations following oral administration occur within 1 to 4 hours and a linear relationship between dose and plasma concentration is observed in the dose range of 100 to 600mg. Mexiletine is weakly bound to plasma proteins (70%). Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals.

Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours). It undergoes stereoselective disposition caused by extensive metabolism. Eleven metabolites of mexiletine are presently known, but none of these metabolites possesses any pharmacological activity. The major metabolites are hydroxymethyl-mexiletine, p-hydroxy-mexiletine, m-hydroxy-mexiletine and N-hydroxy-mexiletine. Formation of hydroxymethyl-mexiletine, p-hydroxy-mexiletine and m-hydroxy-mexiletine is genetically determined and cosegregates with polymorphic debrisoquine 4-hydroxylase [cytochrome P450 (CYP) 2D6] activity. On the other hand, CYP1A2 seems to be implicated in the N-oxidation of mexiletine.

Various physiological, pathological, pharmacological and environmental factors influence the disposition of mexiletine. Myocardial infarction, opioid analgesics, atropine and antacids slow the rate of absorption, whereas metoclopramide enhances it. Rifampicin (rifampin), phenytoin and cigarette smoking significantly enhance the rate of elimination of mexiletine, whereas ciprofloxacin, propafenone and liver cirrhosis decrease it. Cimetidine, ranitidine, fluconazole and omeprazole do not modify the disposition of mexiletine. Conversely, mexiletine is known to alter the disposition of other drugs, such as caffeine and theophylline. Factors affecting the elimination of mexiletine may be clinically important and dosage adjustments are often necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Campbell NPS, Kelly JG, Shanks RG, et al. Mexiletine (Kö 1173) in the management of ventricular dysrhythmias. Lancet 1973; II: 404–7.

    Article  Google Scholar 

  2. Campbell RWF, Dolder MA, Prescott LF, et al. Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction. Lancet 1975; I: 1257–9.

    Article  Google Scholar 

  3. Talbot RG, Nimmo J, Julian DG, et al. Treatment of ventricular arrhythmias with mexiletine (Kö 1173). Lancet 1973; II: 399–403.

    Article  Google Scholar 

  4. Chew CYC, Collett J, Singh BN. Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias. Drugs 1979; 17: 161–81.

    Article  PubMed  CAS  Google Scholar 

  5. Akiyama M, Sugimoto T, Uraoka T, et al. Electrophysiological effects of mexiletine in man. Jpn Heart J 1982; 23: 237–9.

    Google Scholar 

  6. Sami M, Lisbona R. Mexiletine: long-term efficacy and hemodynamic actions in patients with ventricular arrhythmia. Can J Cardiol 1985; 1: 251–8.

    PubMed  CAS  Google Scholar 

  7. Stein J, Podrid P, Lown B. Effects of oral mexiletine on left and right ventricular function. Am J Cardiol 1984; 54: 575–8.

    Article  PubMed  CAS  Google Scholar 

  8. Sheldon RS, Duff HJ, Mitchell LB, et al. Effect of oral combination therapy with mexiletine and quinidine on left and right ventricular function. Am Heart J 1988; 115: 1030–6.

    Article  PubMed  CAS  Google Scholar 

  9. Duff HJ, Roden D, Primm RK, et al. Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine. Circulation 1983; 67: 1124–8.

    Article  PubMed  CAS  Google Scholar 

  10. Leahey Jr EB, Heissenbuttel RH, Giardina EGV, et al. Combined mexiletine and propranolol treatment of refractory ventricular tachycardia. BMJ 1980; 281: 357–8.

    Article  PubMed  CAS  Google Scholar 

  11. Valenzuela C, Sanchez-Chapula J. Electrophysiologic interactions between mexiletine-quinidine and mexiletine-ropitoin in guinea pig papillary muscle. J Cardiovasc Pharmacol 1989; 14: 783–9.

    Article  PubMed  CAS  Google Scholar 

  12. Costard-Jaeckle A, Liem BL, Franz MR. Frequency-dependent effect of quinidine, mexiletine and their combination of postrepolarization refractoriness in vivo. J Cardiovasc Pharmacol 1989; 14: 810–7.

    Article  PubMed  CAS  Google Scholar 

  13. Duff HJ, Cannon NJ, Sheldon RS. Mexiletine-quinidine in isolated hearts: an interaction involving the sodium channel. Cardiovasc Res 1989; 23: 584–92.

    Article  PubMed  CAS  Google Scholar 

  14. Duff HJ, Kolodgie FD, Roden DM, et al. Electropharmacologic synergism with mexiletine and quinidine. J Cardiovasc Pharmacol 1986; 8: 840–6.

    PubMed  CAS  Google Scholar 

  15. Duff HJ. Mexiletine-quinidine combination: enhanced antiarrhythmic and electrophysiologic activity in the dog. J Pharmacol Exp Ther 1989; 249: 617–22.

    PubMed  CAS  Google Scholar 

  16. Roden DM, Iansmith DHS, Woosley RL. Frequency-dependent interactions of mexiletine and quinidine on depolarization and repolarization in canine Purkinje fibers. J Pharmacol Exp Ther 1987; 243: 1218–24.

    PubMed  CAS  Google Scholar 

  17. Duff HJ, Rahmberg M, Sheldon RS. Role of quinidine in the mexiletine-quinidine interaction: electrophysiologic correlates of enhanced antiarrhythmic efficacy. J Cardiovasc Pharmacol 1990; 16: 685–92.

    Article  PubMed  CAS  Google Scholar 

  18. Turgeon J, Fiset C, Giguère R, et al. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. J Pharmacol Exp Ther 1991; 259: 789–98.

    PubMed  CAS  Google Scholar 

  19. Yeung-Lai-Wah JA, Murdock CJ, Boone J, et al. Propafenone-mexiletine combination for the treatment of sustained ventricular tachycardia. J Am Coll Cardiol 1992; 20: 547–51.

    Article  PubMed  CAS  Google Scholar 

  20. Valenzuela C, Delpón E, Tamargo J. Electrophysiologic interactions between mexiletine and propafenone in guinea pig papillary muscles. J Cardiovasc Pharmacol 1989; 14: 351–7.

    Article  PubMed  CAS  Google Scholar 

  21. Breithardt G, Seipel I, Abendroth RR. Comparison of the antiarrhythmic efficacy of disopyramide and mexiletine against stimulus-induced ventricular tachycardia. J Cardiovasc Pharmacol 1981; 3: 1026–37.

    Article  PubMed  CAS  Google Scholar 

  22. Lüderitz B, Mletzko R, Jung W, et al. Combination of antiarrhythmic drugs. J Cardiovasc Pharmacol 1991; 17 Suppl. 6: S48–52.

    PubMed  Google Scholar 

  23. Wagner WL, Manz M, Luderitz B. Combination of sotalol with the class IB substances mexiletine or tocainide in complex ventricular extrasystole. Z Kardiol 1987; 76: 296–302.

    PubMed  CAS  Google Scholar 

  24. Greenspan AM, Spielman SR, Webb CR, et al. Efficacy of combination therapy with mexiletine and a type IA agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease. Am J Cardiol 1985; 56: 277–84.

    Article  PubMed  CAS  Google Scholar 

  25. Tanabe T, Takahashi K, Yoshioka K, et al. Evaluation of disopyramide and mexiletine used alone and in combination for ventricular arrhythmias in patients with and without overt heart disease. Int J Cardiol 1991; 32: 303–12.

    Article  PubMed  CAS  Google Scholar 

  26. Toivonen L, Kadish A, Morady F. A prospective comparison of class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia. Circulation 1991; 84: 101–8.

    Article  PubMed  CAS  Google Scholar 

  27. Hoffmann A, Follath F, Burckhardt D. Safe treatment of resistant ventricular arrhythmias with combination of amiodarone and quinidine or mexiletine. Lancet 1983; I: 704–5.

    Article  Google Scholar 

  28. Waleffe A, Mary-Rabine L, Legrand V, et al. Combined mexiletine and amiodarone treatment of refractory recurrent ventricular tachycardia. Am Heart J 1980; 100: 788–93.

    Article  PubMed  CAS  Google Scholar 

  29. Campbell NPS, Kelly JG, Adgey AAJ, et al. The clinical pharmacology of mexiletine. Br J Clin Pharmacol 1978; 6: 103–8.

    Article  PubMed  CAS  Google Scholar 

  30. Peyrieux JC, Boissel JP, Leizorovicz A, et al. Relationship between plasma mexiletine levels at steady-state. Presence of ventricular arrhythmias and side effects. Fundam Clin Pharmacol 1987; 1: 45–57.

    Article  PubMed  CAS  Google Scholar 

  31. Lévy-Prades R, Philip F, Danays T, et al. Pharmacocinétique de la mexilétine et de son métabolite hydroxyméthyle après administration intramusculaire et intraveineuse de mexilétine chez le sujet sain. Therapie 1987; 42: 3–7.

    PubMed  Google Scholar 

  32. Bradbrook ID, Feldschreiber P, Morrison PJ, et al. Plasma mexiletine concentrations following combined oral and intramuscular administration. Eur J Clin Pharmacol 1981; 19: 301–4.

    Article  PubMed  CAS  Google Scholar 

  33. Prescott LF, Pottage A, Clements JA. Absorption, distribution and elimination of mexiletine. Postgrad Med J 1977; 53 Suppl. 1: 50–5.

    PubMed  CAS  Google Scholar 

  34. Häselbarth V, Doevendans JE, Wolf M. Kinetics and bioavailability of mexiletine in healthy subjects. Clin Pharmacol Ther 1981; 29: 729–36.

    Article  PubMed  Google Scholar 

  35. Klein A, Sami M, Selinger K. Mexiletine kinetics in healthy subjects taking cimetidine. Clin Pharmacol Ther 1985; 37: 669–73.

    Article  PubMed  CAS  Google Scholar 

  36. Herzog P, Holtermüller KH, Kasper W, et al. Absorption of mexiletine after treatment with gastric antacids. Br J Clin Pharmacol 1982; 14: 746–7.

    Article  PubMed  CAS  Google Scholar 

  37. Holt DW, Chadwick DE, Campbell RWE Absorption and antiarrhythmic efficacy of sustained-release mexiletine. Clin Ther 1983; 5: 268–78.

    PubMed  CAS  Google Scholar 

  38. Pringle T, Fox J, McNeill JA, et al. Dose independent pharmacokinetics of mexiletine in healthy volunteers. Br J Clin Pharmacol 1986; 21: 319–21.

    Article  PubMed  CAS  Google Scholar 

  39. Campbell NPS, Kelly JG, Adgey AAJ, et al. Mexiletine in normal volunteers. Br J Clin Pharmacol 1978; 6: 372–3.

    Article  PubMed  CAS  Google Scholar 

  40. Broly F, Vandamme N, Libersa C, et al. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation. Br J Clin Pharmacol 1991; 32: 459–66.

    Article  PubMed  CAS  Google Scholar 

  41. Rohrig TP, Harty LE. Postmortem distribution of mexiletine in a fatal overdose. J Anal Toxicol 1994; 18: 354–5.

    PubMed  CAS  Google Scholar 

  42. Turgeon J, Grech-Bélanger O, Gilbert M. Erythrocyte and serum distribution of mexiletine in man. Biopharm Drug Dispos 1987; 8: 571–6.

    Article  PubMed  CAS  Google Scholar 

  43. Lownes HE, Ives TJ. Mexiletine use in pregnancy and lactation. Am J Obstet Gynecol 1987; 157: 446–7.

    PubMed  CAS  Google Scholar 

  44. Timmis AD, Jackson G, Holt DW. Mexiletine for control of ventricular dysrhythmias in pregnancy. Lancet 1980; II: 647–8.

    Article  Google Scholar 

  45. Gregg AR, Tomich PG. Mexiletine use in pregnancy. J Perinatal 1988; 8: 33–5.

    CAS  Google Scholar 

  46. Lewis AM, Patel L, Johnston A, et al. Mexiletine in human blood and breast milk. Postgrad Med J 1981; 57: 546–7.

    Article  PubMed  CAS  Google Scholar 

  47. Kwok DW, Kerr CR, McErlane KM. Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. Xenobiotica 1995; 25: 1127–42.

    Article  PubMed  CAS  Google Scholar 

  48. Beckett AH, Chidomere EC. The identification and analysis of mexiletine and its metabolic products in man. J Pharm Pharmacol 1977; 29: 281–5.

    Article  PubMed  CAS  Google Scholar 

  49. Grech-Bélanger O, Gilbert M, Turgeon J, et al. Effect of cigarette smoking on mexiletine kinetics. Clin Pharmacol Ther 1985; 37: 638–43.

    Article  PubMed  Google Scholar 

  50. Turgeon J, Paré JRJ, Lalande M, et al. Isolation and structural characterization by spectroscopic methods of two glucuronide metabolites of mexiletine after N-oxidation and deamination. Drug Metab Dispos 1992; 20: 762–9.

    PubMed  CAS  Google Scholar 

  51. Grech-Bélanger O, Turgeon J, Lalande M, et al. Metahydroxymexiletine, a new metabolite of mexiletine. Isolation, characterization, and species differences in its formation. Drug Metab Dispos 1991; 19: 458–61.

    PubMed  Google Scholar 

  52. Grech-Bélanger O, Turgeon J, Lalande M. 2,6-Dimethylphenol: a new metabolite of mexiletine. Res Commun Chem Pathol Pharmacol 1987; 58: 53–62.

    PubMed  Google Scholar 

  53. Grech-Bélanger O, Turgeon J, Gilbert M. Stereoselective disposition of mexiletine in man. Br J Clin Pharmacol 1986; 21: 481–7.

    Article  PubMed  Google Scholar 

  54. Kiddie MA, Kaye CM, Turner P, et al. The influence of urinary pH on the elimination of mexiletine. Br J Clin Pharmacol 1974; 1: 229–32.

    Article  PubMed  CAS  Google Scholar 

  55. Kaye CM, Kiddie MA, Turner P. Variable pharmacokinetics of mexiletine. Postgrad Med J 1977; 53 Suppl. 1: 56–8.

    PubMed  CAS  Google Scholar 

  56. Mitchell BG, Clements JA, Pottage A, et al. Mexiletine disposition: individual variation in response to urine acidification and alkalinisation. Br J Clin Pharmacol 1983; 16: 281–4.

    Article  PubMed  CAS  Google Scholar 

  57. Johnston A, Burgess CD, Henry JA, et al. Mexiletine elimination: influence of urinary pH and volume. Br J Pharmacol 1981; 72: 135P.

    Google Scholar 

  58. Beckett AH, Chidomere EC. The distribution, metabolism and excretion of mexiletine in man. Postgrad Med J 1977; 53 Suppl. 1: 60–6.

    PubMed  CAS  Google Scholar 

  59. Johnston A, Burgess CD, Warrington SJ, et al. The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers. Br J Clin Pharmacol 1979; 8: 349–52.

    Article  PubMed  CAS  Google Scholar 

  60. Pentikäinen PJ, Hietakorpi S, Halinen MO, et al. Cirrhosis of the liver markedly impairs the elimination of mexiletine. Eur J Clin Pharmacol 1986; 30: 83–8.

    Article  PubMed  Google Scholar 

  61. Lledó P, Abrams SML, Johnston A, et al. Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. Eur J Clin Pharmacol 1993; 44: 63–7.

    Article  PubMed  Google Scholar 

  62. Clark RA, Julian DG, Nimmo J, et al. Clinical pharmacological studies of Kö 1173: a new antiarrhythmic agent. Proc Br Pharmacol Soc 1973; 47: 622P–3P.

    CAS  Google Scholar 

  63. Wing LMH, Meffin PJ, Grygiel JJ, et al. The effect of metoclopramide and atropine on the absorption of orally administered mexiletine. Br J Clin Pharmacol 1980; 9: 505–9.

    PubMed  CAS  Google Scholar 

  64. Begg EJ, Chinwah PM, Webb C, et al. Enhanced metabolism of mexiletine after phenytoin administration. Br J Clin Pharmacol 1982; 14: 219–23.

    Article  PubMed  CAS  Google Scholar 

  65. Pentikäinen PJ, Koivula IH, Hiltunen HA. Effect of rifampicin treatment on the kinetics of mexiletine. Eur J Clin Pharmacol 1982; 23: 261–6.

    Article  PubMed  Google Scholar 

  66. Santoni Y, Bruno R, Fornaris M, et al. Pharmacocinétique et biodisponibilité relative chez le sujet sain d’une nouvelle forme orale de mexilétine à libération continue. Therapie 1983; 38: 341–4.

    PubMed  CAS  Google Scholar 

  67. Grech-Bélanger O, Barbeau G, Kishka P, et al. Pharmacokinetics of mexiletine in the elderly. J Clin Pharmacol 1989; 29: 311–5.

    PubMed  Google Scholar 

  68. Paczkowski D, Sadowski Z, Filipek M, et al. Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects. Pol J Pharmacol Pharm 1990; 42: 365–76.

    PubMed  CAS  Google Scholar 

  69. Katagiri Y, Nagasako S, Hayashibara M, et al. Salivary excretion of mexiletine in normal healthy volunteers. J Pharm Pharmacol 1991; 43: 513–5.

    Article  PubMed  CAS  Google Scholar 

  70. Broly F, Vandamme N, Caron J, et al. Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine. Life Sci 1991; 48: PL–123–8.

    Article  Google Scholar 

  71. Ueno K, Yamaguchi R, Tanaka K, et al. Lack of a kinetic interaction between fluconazole and mexiletine. Eur J Clin Pharmacol 1996; 50: 129–31.

    Article  PubMed  CAS  Google Scholar 

  72. Kusumoto M, Ueno K, Tanaka K, et al. Lack of pharmacokinetic interaction between mexiletine and omeprazole. Ann Pharmacother 1998; 32: 182–4.

    Article  PubMed  CAS  Google Scholar 

  73. Labbé L. Rôle du CYP1A2 dans la pharmacocinétique de la mexilétine chez l’human [thesis]. Quebec City (Quebec): Laval University, 1995.

    Google Scholar 

  74. El Allaf D, Henrard L, Crochelet L, et al. Pharmacokinetics of mexiletine in renal insufficiency. Br J Clin Pharmacol 1982; 14: 431–5.

    Article  PubMed  Google Scholar 

  75. El Allaf D, Carlier J, Dressé A. Effects of age on the pharmacokinetics of mexiletine. Int J Clin Pharmacol Res 1986; 6: 303–7.

    PubMed  Google Scholar 

  76. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584–6.

    Article  PubMed  CAS  Google Scholar 

  77. Steiner E, Bertilsson L, Sawe J, et al. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988; 44: 431–5.

    Article  PubMed  CAS  Google Scholar 

  78. Price Evans DA, Mahgoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17: 102–5.

    Article  Google Scholar 

  79. Zanger UM, Vilbois F, Hardwick JP, et al. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988; 27: 5447–54.

    Article  PubMed  CAS  Google Scholar 

  80. Dayer P, Kronbach T, Eichelbaum M, et al. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1′-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency. Biochem Pharmacol 1987; 36: 4145–52.

    Article  PubMed  CAS  Google Scholar 

  81. Kagimoto M, Heim M, Kagimoto K, et al. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 1990; 265: 17209–14.

    PubMed  CAS  Google Scholar 

  82. Broly F, Libersa C, Lhermitte M. Mexiletine metabolism in vitro by human liver. Drug Metab Dispos 1990; 18: 362–8.

    PubMed  CAS  Google Scholar 

  83. Broly F, Libersa C, Lhermitte M, et al. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem Pharmacol 1990; 39: 1045–53.

    Article  PubMed  CAS  Google Scholar 

  84. Sesardic D, Boobis AR, Edwards RJ, et al. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988; 26: 363–72.

    Article  PubMed  CAS  Google Scholar 

  85. Nakajima M, Kobayashi K, Shimada N, et al. Involvement of CYP1A2 in mexiletine metabolism. Br J Clin Pharmacol 1998; 46: 55–62.

    Article  PubMed  CAS  Google Scholar 

  86. Abolfathi Z, Pakdel H, Beaune P, et al. CYP1A2 is the major enzyme involved in the N-oxidation of mexiletine in man [abstract]. Clin Pharmacol Ther 1995; 57: 215.

    Google Scholar 

  87. Sesardic D, Boobis AR, Murray BP, et al. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 1990; 29: 651–63.

    Article  PubMed  CAS  Google Scholar 

  88. Turgeon J, Uprichard ACG, Bélanger PM, et al. Resolution and electrophysiological effects of mexiletine enantiomers. J Pharm Pharmacol 1991; 43: 630–5.

    Article  PubMed  CAS  Google Scholar 

  89. Hill RJ, Duff HJ, Sheldon RS. Determinants of stereospecific binding of type 1 antiarrhythmic drugs to cardiac sodium channels. Mol Pharmacol 1988; 34: 659–63.

    PubMed  CAS  Google Scholar 

  90. De Luca A, Natuzzi F, Lentini G, et al. Stereoselective effects of mexiletine enantiomers on sodium currents and excitability characteristics of adult skeletal muscle fibers. Naunyn Schmiedebergs Arch Pharmacol 1995; 352: 653–61.

    Article  PubMed  Google Scholar 

  91. Igwemezie L, Kerr CR, McErlane KM. The pharmacokinetics of the enantiomers of mexiletine in humans. Xenobiotica 1989; 19: 677–82.

    Article  PubMed  CAS  Google Scholar 

  92. McErlane KM, Igwemezie L, Kerr CR. Stereoselective serum protein binding of mexiletine enantiomers in man. Res Commun Chem Pathol Pharmacol 1987; 56: 141–4.

    PubMed  CAS  Google Scholar 

  93. Abolfathi Z, Fiset C, Gilbert M, et al. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans. J Pharmacol Exp Ther 1993; 266: 1196–201.

    PubMed  CAS  Google Scholar 

  94. Labbé L, Abolfathi Z, Robitaille NM, et al. Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine. Ther Drug Monit 1999; 21: 191–9.

    Article  PubMed  Google Scholar 

  95. Lanchote VL, Cesarino EJ, Santos VJ, et al. Enantioselectivity in the metabolism of mexiletine by conjugation in female patients with the arrhythmic form of chronic Chagas’ heart disease. Chirality 1999; 11: 29–32.

    Article  PubMed  CAS  Google Scholar 

  96. Lanchote VL, Cesarino EJ, Santos VJ, et al. Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias. Eur J Drug Metab Pharmacokinet 1998; 23: 259–66.

    Article  PubMed  CAS  Google Scholar 

  97. Lanchote VL, Bonato PS, Cesarino EJ, et al. HPLC determination of the enantiomeric metabolites of mexiletine in human plasma. Chirality 1997; 9: 722–6.

    Article  PubMed  Google Scholar 

  98. Vandamme N, Broly F, Libersa C, et al. Stereoselective hydroxylation of mexiletine in human liver microsomes: implication of P450IID6. A preliminary report. J Cardiovasc Pharmacol 1993; 21: 77–83.

    Article  PubMed  CAS  Google Scholar 

  99. Knoche B, Gehrcke B, Konig WA, et al. Determination of the enantiomeric composition of mexiletine and its four hydroxylated metabolites in urine by enantioselective capillary gas chromatography. Chirality 1996; 8: 30–4.

    Article  PubMed  CAS  Google Scholar 

  100. Ueno K, Kawaguchi Y, Tanaka K. Pharmacokinetics of mexiletine in middle-aged and elderly patients. Clin Pharmacokinet 1993; 12: 768–70.

    CAS  Google Scholar 

  101. Uenaka K, Koue T, Iwai T, et al. Population pharmacokinetic analysis of mexiletine in adult arrhythmic patients in Japanese population. Biol Pharm Bull 1998; 21: 844–6.

    Article  PubMed  CAS  Google Scholar 

  102. Fukagawa NF, Bandini LG, Young JB. Effect of age on body composition and resting metabolic rate. Am J Physiol 1990; 259: E233–8.

    PubMed  CAS  Google Scholar 

  103. Nitsch J, Steinbeck G, Lüderitz B. Effect of kidney, liver or heart insufficiency on blood mexiletine levels. Internist 1982; 23: 291–3.

    PubMed  CAS  Google Scholar 

  104. Nitsch J, Steinbeck G, Luderitz B. Increase of mexiletine plasma levels due to delayed hepatic metabolism in patients with chronic liver disease. Eur Heart J 1983; 4: 810–4.

    PubMed  CAS  Google Scholar 

  105. Wang T, Wuellner D, Woosley RL, et al. Pharmacokinetics and nondialyzability of mexiletine in renal failure. Clin Pharmacol Ther 1985; 37: 649–53.

    Article  PubMed  CAS  Google Scholar 

  106. Herbinger W, Kramar R, Fridrik M, et al. Pharmakokinetische Untersuchungen mit mexiletin bei patienten mit niereninsuffizienz. Adv Clin Pharmacol 1978; 16: 17–27.

    PubMed  CAS  Google Scholar 

  107. Baudinet G, Henrard L, Quinaux N, et al. Pharmacokinetics of mexiletine in renal insufficiency. Acta Cardiol 1980; 25: 55–65.

    Google Scholar 

  108. Evers J, Messer W, Aboudan F, et al. Mexiletine in terminal renal failure and various dialysis procedures. Klin Wochenschr 1989; 67: 995–8.

    Article  PubMed  CAS  Google Scholar 

  109. Jones TE, Reece PA, Fisher GC. Mexiletine removal by peritoneal dialysis. Eur J Clin Pharmacol 1983; 25: 839–40.

    Article  PubMed  CAS  Google Scholar 

  110. Guay DRP, Meatherall RC, Ferguson I, et al. Mexiletine clearance during peritoneal dialysis. Br J Clin Pharmacol 1985; 19: 857–8.

    Article  PubMed  CAS  Google Scholar 

  111. Pentikäinen PJ, Halinen MO, Helin MJ. Pharmacokinetics of intravenous mexiletine in patients with acute myocardial infarction. J Cardiovasc Pharmacol 1984; 6: 1–6.

    Article  PubMed  Google Scholar 

  112. Pentikäinen PJ, Halinen MO, Helin MJ. Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. Eur J Clin Pharmacol 1983; 25: 773–7.

    Article  PubMed  Google Scholar 

  113. Pottage A, Campbell RWF, Achuff SC, et al. The absorption of oral mexiletine in coronary care patients. Eur J Clin Pharmacol 1978; 13: 393–9.

    Article  Google Scholar 

  114. Lévy-Prades R, Philip F, Danays T, et al. Mexiletine in acute myocardial infarction. Simulation of a theoretical protocol and validation in six patients. Drug Res 1989; 39: 903–8.

    Google Scholar 

  115. Leahey Jr EB, Giardina EGV, Bigger Jr JT. Effect of ventricular failure on steady state kinetics of mexiletine [abstract]. Clin Res 1980; 28: 239A.

    Google Scholar 

  116. Vozeh S, Katz G, Steiner V, et al. Population pharmacokinetic parameters in patients treated with oral mexiletine. Eur J Clin Pharmacol 1982; 23: 445–51.

    Article  PubMed  CAS  Google Scholar 

  117. Ohashi K, Ebihara A, Hashimoto T, et al. Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias. Drug Res 1984; 34: 503–7.

    CAS  Google Scholar 

  118. Nattel S, Heger JJ, Rinkenberger RL, et al. The pharmacokinetics of mexiletine in patients with refractory ventricular arrhythmias [abstract]. Clin Res 1979; 27: 445A.

    Google Scholar 

  119. Heger JJ, Nattel S, Rinkenberger RL, et al. Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia. Am J Cardiol 1980; 45: 627–32.

    Article  PubMed  CAS  Google Scholar 

  120. Hutt V, Pabst G, Salama Z, et al. Untersuchungen zur pharmakokinetik und bioverfugbarkeit einer neuen mexiletin-zubereitung an gesunden freiwilligen. Drug Res 1995; 45: 254–7.

    CAS  Google Scholar 

  121. Bruno R, Santoni Y, Iliadis A, et al. Simultaneous modelling of mexiletine and hydroxy-methyl-mexiletine data after single-and multiple-dose administration of a sustained-release mexiletine formulation. Biopharm Drug Disp 1992; 13: 481–93.

    Article  CAS  Google Scholar 

  122. Cereghino JJ, Wilder BJ, Kupferberg HJ, et al. A single-dose study of mexiletine (Kö 1173). Epilepsia 1975; 16: 665–72.

    Article  PubMed  CAS  Google Scholar 

  123. Cereghino JJ, Brock JT, Van Meter JC, et al. A multiple-dose study of mexiletine (Kö 1173). Epilepsia 1975; 16: 673–7.

    Article  PubMed  CAS  Google Scholar 

  124. Kiddie MA, Royds RB, Shaw TRD. Preliminary studies on the pharmacology of an antidysrhythmic, Kö 1173, in man. Proc Br Pharmacol Soc 1973; 47: 674–5P.

    Google Scholar 

  125. Paalman ACA, Roos JC, Siebelink J, et al. Development of a dosage scheme for simultaneous intravenous and oral administration of mexiletine. Postgrad Med J 1977; 53 Suppl. 1: 128–32.

    PubMed  Google Scholar 

  126. Upward JW, Holt DW, Jackson G. A study to compare the efficacy, plasma concentration profile and tolerability of conventional mexiletine and slow-release mexiletine. Eur Heart J 1984; 5: 247–52.

    PubMed  CAS  Google Scholar 

  127. Smyllie HC, Doar JWH, Head CD, et al. A trial of intravenous and oral mexiletine in acute myocardial infarction. Eur J Clin Pharmacol 1984; 26: 537–42.

    Article  PubMed  CAS  Google Scholar 

  128. Nimmo WS, Heading RC, Wilson J, et al. Inhibition of gastric emptying and drug absorption by narcotic analgesics. Br J Clin Pharmacol 1975; 2: 509–13.

    Article  PubMed  CAS  Google Scholar 

  129. Joeres R, Klinker H, Heusler H, et al. Influence of mexiletine on caffeine elimination. Pharmacol Ther 1987; 33: 163–9.

    Article  PubMed  CAS  Google Scholar 

  130. Butler MA, Iwasaki M, Guengerich FP, et al. Human cytochrome P-450pa (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989; 86: 7696–700.

    Article  PubMed  CAS  Google Scholar 

  131. Berthou F, Flinois JP, Ratanasavanh D, et al. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos 1991; 19: 561–7.

    PubMed  CAS  Google Scholar 

  132. Ha HR, Chen J, Freiburghaus AU, et al. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995; 39: 321–6.

    Article  PubMed  CAS  Google Scholar 

  133. Ueno K, Miyai K, Seki T, et al. Interaction between theophylline and mexiletine. Ann Pharmacother 1990; 24: 471–2.

    CAS  Google Scholar 

  134. Stanley R, Comer T, Taylor JL, et al. Mexiletine-theophylline interaction. Am J Med 1989; 86: 733–4.

    Article  PubMed  CAS  Google Scholar 

  135. Ueno K, Miyai K, Kato M, et al. Mechanism of interaction between theophylline and mexiletine. Ann Pharmacother 1991; 25: 727–30.

    CAS  Google Scholar 

  136. Loi CM, Wei X, Vestal RE. Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. Clin Pharmacol Ther 1991; 49: 571–80.

    Article  PubMed  CAS  Google Scholar 

  137. Stoysich AM, Mohiuddin SM, Destache CJ, et al. Influence of mexiletine on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 1991; 31: 354–7.

    PubMed  CAS  Google Scholar 

  138. Katz A, Buskila D, Sukenik S. Oral mexiletine-theophylline interaction. Int J Cardiol 1987; 17: 227–8.

    Article  PubMed  CAS  Google Scholar 

  139. Kendall JD, Chrymko MM, Cooper BE. Theophylline-mexiletine interaction: a case report. Pharmacotherapy 1992; 12: 416–8.

    PubMed  CAS  Google Scholar 

  140. Hurwitz A, Vacek JL, Botteron GW, et al. Mexiletine effects on theophylline disposition. Clin Pharmacol Ther 1991; 50: 299–307.

    Article  PubMed  CAS  Google Scholar 

  141. Inafuku M, Suzuki T, Ohtsu F, et al. The effect of mexiletine on theophylline pharmacokinetics in patients with bronchial asthma. J Cardiol 1992; 22: 227–33.

    PubMed  CAS  Google Scholar 

  142. Kessler KM, Interian Jr A, Cox M, et al. Proarrhythmia related to a kinetic and dynamic interaction of mexiletine and theophylline. Am Heart J 1989; 117: 964–6.

    Article  PubMed  CAS  Google Scholar 

  143. Fuhr U, Strobl G, Manaut F, et al. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol Pharmacol 1993; 43: 191–9.

    PubMed  CAS  Google Scholar 

  144. Healy DP, Polk RE, Kanawati L, et al. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother 1989; 33: 474–8.

    Article  PubMed  CAS  Google Scholar 

  145. Brockmeyer NH, Breithaupt H, Ferdinand W, et al. Kinetics of oral and intravenous mexiletine: lack of effect of cimetidine and ranitidine. Eur J Clin Pharmacol 1989; 36: 375–8.

    Article  PubMed  CAS  Google Scholar 

  146. Leahey Jr EB, Reiffei JA, Giardina EGV, et al. The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin. Ann Intern Med 1980; 92: 605–8.

    PubMed  Google Scholar 

  147. Saris SD, Lowenthal DT, Affrime MB. Steady-state digoxin concentration during oral mexiletine administration. Curr Ther Res 1983; 34: 662–6.

    CAS  Google Scholar 

  148. Labbé L. Metabolisme de la mexiletine chaz l’humain: role of CYP1A2 et interaction ave la propafenome [thesis]. Quebec City (Quebec): Laval University, 1999.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Quebec Heart Institute and Faculty of Pharmacy, Laval University, Ste-Foy, Quebec, Canada

    Line Labbé &  Jacques Turgeon

  2. Faculty of Medicine, Laval University, Ste-Foy, Quebec, Canada

    Jacques Turgeon

  3. Phoenix International Life Sciences, 2350 rue Cohen, St Laurant, Québec, H4R 2N6, Canada

    Jacques Turgeon

Authors
  1. Line Labbé
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacques Turgeon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacques Turgeon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Labbé, L., Turgeon, J. Clinical Pharmacokinetics of Mexiletine. Clin Pharmacokinet 37, 361–384 (1999). https://doi.org/10.2165/00003088-199937050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199937050-00002

Keywords

Search

Navigation